Application of nicotine enantiomers, derivatives and analogues in therapy of neurodegenerative disorders.

[1]  J. Segura-Aguilar,et al.  Novel mechanisms and approaches in the study of neurodegeneration and neuroprotection. A review , 2009, Neurotoxicity Research.

[2]  Jinchao Shen,et al.  Determination of tobacco alkaloids by gas chromatography–mass spectrometry using cloud point extraction as a preconcentration step , 2006 .

[3]  Anna M. Lee,et al.  CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment , 2006, Neuropharmacology.

[4]  F. LaFerla,et al.  The role of nicotinic acetylcholine receptors in Alzheimer’s disease , 2006, Journal of Physiology-Paris.

[5]  E. Levin,et al.  Chronic nicotine interactions with clozapine and risperidone and attentional function in rats , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[6]  Robert C. Smith,et al.  Effects of Nicotine Nasal Spray on Cognitive Function in Schizophrenia , 2006, Neuropsychopharmacology.

[7]  O. Nielsen,et al.  [Transdermal nicotine treatment of ulcerative colitis: a survey of a Cochrane review]. , 2006, Ugeskrift for laeger.

[8]  M. Quik,et al.  Striatal α6* Nicotinic Acetylcholine Receptors: Potential Targets for Parkinson's Disease Therapy , 2006, Journal of Pharmacology and Experimental Therapeutics.

[9]  C. Scully,et al.  Nicotine, smoke and patches , 2006, British dental journal.

[10]  S. Punnoose,et al.  Nicotine for schizophrenia. , 2006, The Cochrane database of systematic reviews.

[11]  J. Buccafusco,et al.  Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition. , 2006, CNS drug reviews.

[12]  F. Joseph McClernon,et al.  Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization , 2006, Psychopharmacology.

[13]  A. Terry,et al.  Repeated nicotine exposure in rats: Effects on memory function, cholinergic markers and nerve growth factor , 2005, Neuroscience.

[14]  J. Daly,et al.  A revised structure for alkaloid 235C isolated from skin extracts of mantellid (Mantella) frogs of Madagascar. , 2005, Journal of natural products.

[15]  P. Facchini,et al.  Synthesis and trafficking of alkaloid biosynthetic enzymes. , 2005, Current opinion in plant biology.

[16]  J. Daly,et al.  Alkaloids from amphibian skin: a tabulation of over eight-hundred compounds. , 2005, Journal of natural products.

[17]  E. Bézard,et al.  Investigating the Receptor-independent Neuroprotective Mechanisms of Nicotine in Mitochondria* , 2005, Journal of Biological Chemistry.

[18]  S. Streiff,et al.  Enantioselective synthesis of (+)(R)- and (-)(S)-nicotine based on Ir-catalysed allylic amination. , 2005, Organic & biomolecular chemistry.

[19]  S. Machado,et al.  Electrochemical Behavior of Nicotine Studied by Voltammetric Techniques at Boron‐Doped Diamond Electrodes , 2005 .

[20]  E. Barreiro,et al.  New selective acetylcholinesterase inhibitors designed from natural piperidine alkaloids. , 2005, Bioorganic & medicinal chemistry.

[21]  N. Greig,et al.  Cholinesterases: roles in the brain during health and disease. , 2005, Current Alzheimer research.

[22]  Xiulan Sun,et al.  Desensitized nicotinic receptors in brain , 2005, Brain Research Reviews.

[23]  J. Daly.  Nicotinic Agonists, Antagonists, and Modulators From Natural Sources , 2005, Cellular and Molecular Neurobiology.

[24]  J. Sussman,et al.  Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology. , 2005, Current opinion in pharmacology.

[25]  E. Levin,et al.  Olanzapine interactions with nicotine and mecamylamine in rats: effects on memory function. , 2005, Neurotoxicology and teratology.

[26]  S. Chapman,et al.  Nicotine analogues: a review of tobacco industry research interests. , 2005, Addiction.

[27]  F. LaFerla,et al.  Alzheimer's disease: Aβ, tau and synaptic dysfunction , 2005 .

[28]  R. Tyndale,et al.  Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence , 2005, Clinical pharmacology and therapeutics.

[29]  Neal L. Benowitz,et al.  Metabolism and Disposition Kinetics of Nicotine , 2005, Pharmacological Reviews.

[30]  J. Mosiewicz,et al.  Pharmacokinetics and metabolism of nicotine. , 2005, Pharmacological reports : PR.

[31]  F. LaFerla,et al.  Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Srinivasan,et al.  Nicotine attenuates morphological deficits in a contusion model of spinal cord injury. , 2005, Journal of neurotrauma.

[33]  C. Schöneich.  Methionine oxidation by reactive oxygen species: reaction mechanisms and relevance to Alzheimer's disease. , 2005, Biochimica et biophysica acta.

[34]  D. A. Dougherty,et al.  Using physical chemistry to differentiate nicotinic from cholinergic agonists at the nicotinic acetylcholine receptor. , 2005, Journal of the American Chemical Society.

[35]  M. Nakajima,et al.  TRANS-3′-HYDROXYCOTININE O- AND N-GLUCURONIDATIONS IN HUMAN LIVER MICROSOMES , 2005, Drug Metabolism and Disposition.

[36]  E. Levin,et al.  Haloperidol increases smoking in patients with schizophrenia , 1995, Psychopharmacology.

[37]  G. Wetscher,et al.  In Vitro free radical production in rat esophageal mucosa induced by nicotine , 1995, Digestive Diseases and Sciences.

[38]  M. Schorderet,et al.  Alzheimer's disease: fundamental and therapeutic aspects , 1995, Experientia.

[39]  Volker Rahlfs,et al.  Absorption of nicotine through the oral mucosa I. Measurement of nicotine concentration in the blood after application of nicotine and total particulate matter , 1973, Agents and Actions.

[40]  S. Hecht,et al.  Cytochrome P450 2A-catalyzed metabolic activation of structurally similar carcinogenic nitrosamines: N'-nitrosonornicotine enantiomers, N-nitrosopiperidine, and N-nitrosopyrrolidine. , 2005, Chemical research in toxicology.

[41]  A. Rauk,et al.  Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity. , 2005, Medical hypotheses.

[42]  G. Dunbar,et al.  TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. , 2006, CNS drug reviews.

[43]  J. Buccafusco,et al.  Novel analogs of choline as potential neuroprotective agents. , 2005, Journal of Alzheimer's disease : JAD.

[44]  S. Scheff,et al.  Nicotinic Receptor Modulation for Neuroprotection and Enhancement of Functional Recovery Following Brain Injury or Disease , 2004, Annals of the New York Academy of Sciences.

[45]  Z. Xu,et al.  Comparison of volatile and semivolatile compounds from commercial cigarette by supercritical fluid extraction and simultaneous distillation extraction , 2004, Journal of Zhejiang University. Science.

[46]  D. Lewis,et al.  Cytochromes P450 in the bioactivation of chemicals. , 2004, Current topics in medicinal chemistry.

[47]  Jerry J Buccafusco,et al.  Neuronal nicotinic receptor subtypes: defining therapeutic targets. , 2004, Molecular interventions.

[48]  K. Tipton,et al.  Electrochemical investigation into the redox activity of Fe(II)/Fe(III) in the presence of nicotine and possible relations to neurodegenerative diseases. , 2004, Biochimica et biophysica acta.

[49]  M. Quik.  Smoking, nicotine and Parkinson's disease , 2004, Trends in Neurosciences.

[50]  Sason Shaik,et al.  Mechanism of oxidation reactions catalyzed by cytochrome p450 enzymes. , 2004, Chemical reviews.

[51]  A. Breland,et al.  Urine cotinine as an index of smoking status in smokers during 96-hr abstinence: comparison between gas chromatography/mass spectrometry and immunoassay test strips. , 2004, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[52]  T. Fukami,et al.  Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[53]  S. Frucht.  Parkinson Disease: An Update , 2004, The neurologist.

[54]  S. Hecht,et al.  Stereoselective metabolism and tissue retention in rats of the individual enantiomers of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), metabolites of the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). , 2004, Carcinogenesis.

[55]  N. Benowitz,et al.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity , 2004, Clinical pharmacology and therapeutics.

[56]  R. Freedman,et al.  Effects of Nicotine on Cognitive Deficits in Schizophrenia , 2004, Neuropsychopharmacology.

[57]  E. Perry,et al.  Nicotine reduces Aβ in the brain and cerebral vessels of APPsw mice , 2004, The European journal of neuroscience.

[58]  D. Yildiz.  Nicotine, its metabolism and an overview of its biological effects. , 2004, Toxicon : official journal of the International Society on Toxinology.

[59]  P. Adams,et al.  Pharmacological characterization of SIB-1663, a conformationally rigid analog of nicotine , 2004, Brain Research.

[60]  V. Knott,et al.  Clinical and attentional effects of acute nicotine treatment in Tourette’s syndrome , 2004, European Psychiatry.

[61]  Hyung-Kyoon Choi,et al.  Metabolic fingerprinting of wild type and transgenic tobacco plants by 1H NMR and multivariate analysis technique. , 2004, Phytochemistry.

[62]  P. Dhar.  Measuring tobacco smoke exposure: quantifying nicotine/cotinine concentration in biological samples by colorimetry, chromatography and immunoassay methods. , 2004, Journal of pharmaceutical and biomedical analysis.

[63]  T. Sixma,et al.  Nicotine and Carbamylcholine Binding to Nicotinic Acetylcholine Receptors as Studied in AChBP Crystal Structures , 2004, Neuron.

[64]  A. Nordberg,et al.  Reduced levels of Aβ 40 and Aβ 42 in brains of smoking controls and Alzheimer's patients , 2004, Neurobiology of Disease.

[65]  E. Levin,et al.  Nicotine-antipsychotic drug interactions and attentional performance in female rats. , 2004, European journal of pharmacology.

[66]  D. Pogocki.  Mutation of the Phe20 residue in Alzheimer's amyloid beta-peptide might decrease its toxicity due to disruption of the Met35-cupric site electron transfer pathway. , 2004, Chemical research in toxicology.

[67]  Qiang Liu,et al.  Nicotine attenuates β‐amyloid peptide‐induced neurotoxicity, free radical and calcium accumulation in hippocampal neuronal cultures , 2004, British journal of pharmacology.

[68]  J. Changeux,et al.  Rational understanding of nicotinic receptors drug binding. , 2004, Current topics in medicinal chemistry.

[69]  M. Jarvis.  Why people smoke , 2004, BMJ : British Medical Journal.

[70]  R. Pugmire,et al.  Solid-state 15N NMR studies of tobacco leaves. , 2004, Journal of agricultural and food chemistry.

[71]  Nigel J Fullwood,et al.  Both the D-(+) and L-(-) enantiomers of nicotine inhibit Abeta aggregation and cytotoxicity. , 2004, Biochemistry.

[72]  J. Woods,et al.  Cardiovascular Effects of Nicotine, Chlorisondamine, and Mecamylamine in the Pigeon , 2004, Journal of Pharmacology and Experimental Therapeutics.

[73]  A. Lawrence,et al.  The Cognitive Psychopharmacology of Alzheimer's Disease: Focus on Cholinergic Systems , 1998, Neurochemical Research.

[74]  A. Nordberg,et al.  The competition of (−)-[3H]nicotine binding by the enantiomers of nicotine, nornicotine and anatoxin-a in membranes and solubilized preparations of different brain regions of rat , 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.

[75]  D. Comar,et al.  Nicotine-11C: Synthesis and distribution kinetics in animals , 1976, European Journal of Nuclear Medicine.

[76]  S. Kang,et al.  Synthesis and Characterization of Pseudotetrahedral Copper(II) Dihalide Complexes with (s)-(−)-Nicotine , 2004 .

[77]  W. Kübler,et al.  Nicotine and sympathetic neurotransmission , 2004, Cardiovascular Drugs and Therapy.

[78]  G. Perry,et al.  Sources and mechanisms of cytoplasmic oxidative damage in Alzheimer's disease. , 2004, Acta neurobiologiae experimentalis.

[79]  D. Elbaum,et al.  Neurodegenerative aspects of protein aggregation. , 2004, Acta neurobiologiae experimentalis.

[80]  S. Shimohama,et al.  Alzheimer's disease and acetylcholine receptors. , 2004, Acta neurobiologiae experimentalis.

[81]  P. Liberski,et al.  Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease. , 2004, Acta neurobiologiae experimentalis.

[82]  R. Schreiber,et al.  AR-R 17779 improves social recognition in rats by activation of nicotinic α7 receptors , 2004, Psychopharmacology.

[83]  Calin B Chiribau,et al.  Characterization of HdnoR, the Transcriptional Repressor of the 6-Hydroxy-D-nicotine Oxidase Gene of Arthrobacter nicotinovorans pAO1, and its DNA-binding Activity in Response to L- and D-Nicotine Derivatives* , 2003, Journal of Biological Chemistry.

[84]  Z. Bikádi,et al.  Muscarinic and nicotinic cholinergic agonists: structural analogies and discrepancies. , 2003, Current medicinal chemistry.

[85]  Stephen S. Hecht,et al.  Tobacco carcinogens, their biomarkers and tobacco-induced cancer , 2003, Nature Reviews Cancer.

[86]  Jeffrey P. Jones,et al.  Crystallographic studies on the complex behavior of nicotine binding to P450cam (CYP101). , 2003, Biochemistry.

[87]  M. Berthelot,et al.  The nicotinic pharmacophore: thermodynamics of the hydrogen-bonding complexation of nicotine, nornicotine, and models. , 2003, The Journal of organic chemistry.

[88]  J. Lindstrom.  Nicotinic Acetylcholine Receptors of Muscles and Nerves , 2003 .

[89]  Donato A Di Monte,et al.  The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet Neurology.

[90]  D. Sheehan,et al.  The Tourette's Disorder Scale (TODS) , 2003, Assessment.

[91]  M. Hupé,et al.  Effects of moisture content in cigar tobacco on nicotine extraction. Similarity between soxhlet and focused open-vessel microwave-assisted techniques. , 2003, Journal of chromatography. A.

[92]  K. Pope,et al.  Nicotine as an Antiepileptic Agent in ADNFLE: An N‐of‐One Study , 2003, Epilepsia.

[93]  K. Janda,et al.  Glycation of the amyloid β-protein by a nicotine metabolite: A fortuitous chemical dynamic between smoking and Alzheimer's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[94]  R. Tyndale,et al.  CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. , 2003, Pharmacogenetics.

[95]  R. Tyndale,et al.  Decreasing smoking behaviour and risk through CYP2A6 inhibition. , 2003, Drug discovery today.

[96]  J. Buccafusco,et al.  The potential role of cotinine in the cognitive and neuroprotective actions of nicotine. , 2003, Life sciences.

[97]  A. Siderowf,et al.  Update on Parkinson Disease , 2003, Annals of Internal Medicine.

[98]  Björn Eliasson,et al.  Cigarette smoking and diabetes. , 2003, Progress in cardiovascular diseases.

[99]  J. Tillement,et al.  Nicotine protects rat brain mitochondria against experimental injuries , 2003, Neuropharmacology.

[100]  Sharon Miksys,et al.  Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics , 2003, British journal of pharmacology.

[101]  J. Czernin,et al.  Cigarette smoking and coronary blood flow. , 2003, Progress in cardiovascular diseases.

[102]  G. Higgins,et al.  Reversal of a Vigilance Decrement in the Aged Rat by Subtype-Selective Nicotinic Ligands , 2003, Neuropsychopharmacology.

[103]  Lawrence P. Wackett,et al.  Pseudomonas putida—a versatile biocatalyst , 2003, Nature Biotechnology.

[104]  N. Benowitz.  Basic cardiovascular research and its implications for the medicinal use of nicotine. , 2003, Journal of the American College of Cardiology.

[105]  David R. Brown,et al.  Copper-dependent generation of hydrogen peroxide from the toxic prion protein fragment PrP106–126 , 2003, Neuroscience Letters.

[106]  C. R. Craig,et al.  Modern Pharmacology with Clinical Applications , 2003 .

[107]  D. Bertrand,et al.  Nicotinic acetylcholine receptors: from structure to brain function. , 2003, Reviews of physiology, biochemistry and pharmacology.

[108]  D. Pogocki.  Alzheimer's beta-amyloid peptide as a source of neurotoxic free radicals: the role of structural effects. , 2003, Acta neurobiologiae experimentalis.

[109]  J. Ghiso,et al.  Amyloidosis and Alzheimer's disease. , 2002, Advanced drug delivery reviews.

[110]  M. Picciotto,et al.  Nicotinic receptors in aging and dementia. , 2002, Journal of neurobiology.

[111]  E. Levin.  Nicotinic receptor subtypes and cognitive function. , 2002, Journal of neurobiology.

[112]  R. Lester,et al.  Desensitization of neuronal nicotinic receptors. , 2002, Journal of neurobiology.

[113]  J. Changeux,et al.  The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. , 2002, Journal of neurobiology.

[114]  R. Tyndale,et al.  CYP2A6 genetic variation and potential consequences. , 2002, Advanced drug delivery reviews.

[115]  M. Nakajima,et al.  Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. , 2002, British journal of clinical pharmacology.

[116]  P. Bickford,et al.  Nicotine's oxidative and antioxidant properties in CNS. , 2002, Life sciences.

[117]  R. Tyndale,et al.  Drug-metabolizing cytochrome P450s in the brain. , 2002, Journal of psychiatry & neuroscience : JPN.

[118]  R. West.  The deadly weed: Nicotine and tobacco dependence , 2002 .

[119]  E. Levin,et al.  Nicotine Interactions with Haloperidol, Clozapine and Risperidone and Working Memory Function in Rats , 2002, Neuropsychopharmacology.

[120]  T. Inada,et al.  Nicotine suppresses 1-methyl-4-phenylpyridinium ion-induced hydroxyl radical generation in rat striatum , 2002, Neuroscience Letters.

[121]  J. Galligan,et al.  Pharmacological Properties of Nicotinic Acetylcholine Receptors Expressed by Guinea Pig Small Intestinal Myenteric Neurons , 2002, Journal of Pharmacology and Experimental Therapeutics.

[122]  D. Ashley,et al.  Determination of nicotine and other minor alkaloids in international cigarettes by solid-phase microextraction and gas chromatography/mass spectrometry. , 2002, Analytical chemistry.

[123]  J. McEvoy,et al.  The importance of nicotinic acetylcholine receptors in schizophrenia, bipolar disorder and Tourette's syndrome. , 2002, Current drug targets. CNS and neurological disorders.

[124]  E. Levin,et al.  Nicotinic treatment for cognitive dysfunction. , 2002, Current drug targets. CNS and neurological disorders.

[125]  M. O'Neill,et al.  The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. , 2002, Current drug targets. CNS and neurological disorders.

[126]  R. West.  Banning smoking in the workplace , 2002, BMJ : British Medical Journal.

[127]  Ramón Soto-Otero,et al.  Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease. , 2002, Biochemical pharmacology.

[128]  R. Thara,et al.  Smoking in schizophrenia — all is not biological , 2002, Schizophrenia Research.

[129]  B. Hitsman,et al.  Would smokers with schizophrenia benefit from a more flexible approach to smoking treatment? , 2002, Addiction.

[130]  D. Butterfield,et al.  Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer’s amyloid β-peptide 1–42 , 2002, Peptides.

[131]  D. Butterfield,et al.  Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress , 2002 .

[132]  N. Benowitz,et al.  Cardiovascular Effects of Nasal and Transdermal Nicotine and Cigarette Smoking , 2002, Hypertension.

[133]  D. Butterfield,et al.  Substitution of isoleucine-31 by helical-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer’s amyloid β-peptide (1–42) , 2002 .

[134]  N. Benowitz,et al.  Accelerated metabolism of nicotine and cotinine in pregnant smokers. , 2002, The Journal of pharmacology and experimental therapeutics.

[135]  E. Perry,et al.  Chronic nicotine treatment reduces β‐amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw) , 2002, Journal of neurochemistry.

[136]  R. Remmel,et al.  Drug Metabolism Databases and High-Throughput Testing During Drug Design and Development. , 2002 .

[137]  P. Fletcher,et al.  Serotonin-based therapeutics. , 2002, Pharmacology, biochemistry, and behavior.

[138]  S. S. Yang,et al.  Determination of tobacco alkaloids by gas chromatography with nitrogen–phosphorus detection , 2002, Analytical and bioanalytical chemistry.

[139]  D. Butterfield,et al.  Role of glycine-33 and methionine-35 in Alzheimer's amyloid beta-peptide 1-42-associated oxidative stress and neurotoxicity. , 2002, Biochimica et biophysica acta.

[140]  M. Nakajima,et al.  High-performance liquid chromatographic assay for N-glucuronidation of nicotine and cotinine in human liver microsomes. , 2002, Analytical biochemistry.

[141]  R. Tyndale,et al.  The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. , 2002, Pharmacogenomics.

[142]  M. Fiore,et al.  Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. , 2002, Chest.

[143]  J. Changeux,et al.  Models of the extracellular domain of the nicotinic receptors and of agonist- and Ca2+-binding sites , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[144]  J. Buccafusco,et al.  Nicotine increases the expression of high affinity nerve growth factor receptors in both in vitro and in vivo. , 2002, Life sciences.

[145]  R. Tyndale,et al.  Genetic Variation in CYP2A6-Mediated Nicotine Metabolism Alters Smoking Behavior , 2002, Therapeutic drug monitoring.

[146]  M. Quik,et al.  Stimulation of non-α7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture , 2002, Neuroscience.

[147]  E. Perez-stable,et al.  Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. , 2002, Journal of the National Cancer Institute.

[148]  C. Schöneich.  Redox processes of methionine relevant to beta-amyloid oxidation and Alzheimer's disease. , 2002, Archives of biochemistry and biophysics.

[149]  D. Lewis,et al.  Species differences in coumarin metabolism: a molecular modelling evaluation of CYP2A interactions , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[150]  M. Jaskólski,et al.  Prion diseases: a dual view of the prion hypothesis as seen from a distance. , 2002, Acta neurobiologiae experimentalis.

[151]  Jeff W. M. Bulte,et al.  Physics and Chemistry Basis of Biotechnology , 2002, Focus on Biotechnology.

[152]  D. Butterfield.  Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. , 2002, Free radical research.

[153]  Ruben Abagyan,et al.  Structural model of nicotinic acetylcholine receptor isotypes bound to acetylcholine and nicotine , 2002, BMC Structural Biology.

[154]  R. Pittilo.  Cigarette smoking, endothelial injury and cardiovascular disease , 2001 .

[155]  Y. Shachar-Hill,et al.  Plant NMR spectroscopy , 2001 .

[156]  R. Abdool.  The Society for Research in Nicotine and Tobacco--an amazing success story. , 2001 .

[157]  P. Kenny,et al.  Neurobiology of the nicotine withdrawal syndrome , 2001, Pharmacology Biochemistry and Behavior.

[158]  M. Biasi,et al.  Cellular mechanisms of nicotine addiction , 2001, Pharmacology Biochemistry and Behavior.

[159]  M. Quik,et al.  Nicotine administration reduces striatal MPP+ levels in mice , 2001, Brain Research.

[160]  J P Changeux,et al.  The Ligand Gated Ion Channel database: an example of a sequence database in neuroscience. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[161]  J. David Sweatt,et al.  β-Amyloid Activates the Mitogen-Activated Protein Kinase Cascade via Hippocampal α7 Nicotinic Acetylcholine Receptors:In Vitro and In Vivo Mechanisms Related to Alzheimer's Disease , 2001, The Journal of Neuroscience.

[162]  S. Nakamura,et al.  Nicotinic acetylcholine receptors and neurodegenerative disease. , 2001, Alcohol.

[163]  T Yamamoto,et al.  Nicotine metabolism and CYP2A6 allele frequencies in Koreans. , 2001, Pharmacogenetics.

[164]  P. Wirsching,et al.  An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis. , 2001, The Journal of organic chemistry.

[165]  J. Tillement,et al.  In vitro effects of nicotine on mitochondrial respiration and superoxide anion generation , 2001, Brain Research.

[166]  Tønder Je,et al.  Agonists at the a4b2 Nicotinic Acetylcholine Receptors Relationships and Molecular Modelling , 2001 .

[167]  R. Papke,et al.  Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. , 2001, The Journal of pharmacology and experimental therapeutics.

[168]  H. Shibasaki,et al.  α7 Nicotinic Receptor Transduces Signals to Phosphatidylinositol 3-Kinase to Block A β-Amyloid-induced Neurotoxicity* , 2001, The Journal of Biological Chemistry.

[169]  T. George,et al.  Mecamylamine: new therapeutic uses and toxicity/risk profile. , 2001, Clinical therapeutics.

[170]  J. Drago,et al.  Dose‐related neuroprotective effects of chronic nicotine in 6‐hydroxydopamine treated rats, and loss of neuroprotection in α4 nicotinic receptor subunit knockout mice , 2001, British journal of pharmacology.

[171]  R. Carp,et al.  Oxidative Stress and Neurodegeneration in Prion Diseases , 2001, Annals of the New York Academy of Sciences.

[172]  D. Bertrand,et al.  Chronic Exposure to Nicotine Upregulates the Human α4β2 Nicotinic Acetylcholine Receptor Function , 2001, The Journal of Neuroscience.

[173]  T. Cserháti,et al.  Analytical Determination of Nicotine and Related Compounds and their Metabolites , 2001 .

[174]  Bernhard Hennig,et al.  Nicotine protects against arachidonic‐acid‐induced caspase activation, cytochrome c release and apoptosis of cultured spinal cord neurons , 2001, Journal of neurochemistry.

[175]  A. Hama,et al.  The antinociceptive effect of intrathecal administration of epibatidine with clonidine or neostigmine in the formalin test in rats , 2001, Pain.

[176]  Ayhan Demirbas,et al.  Supercritical fluid extraction and chemicals from biomass with supercritical fluids , 2001 .

[177]  F. Fumagalli,et al.  Stimulatory role of dopamine on fibroblast growth factor‐2 expression in rat striatum , 2001, Journal of neurochemistry.

[178]  J. Corwin,et al.  Nicotinic treatment of Alzheimer’s disease , 2001, Biological Psychiatry.

[179]  Edward D Levin,et al.  Cognitive effects of nicotine , 2001, Biological Psychiatry.

[180]  M. Rattray.  Is there nicotinic modulation of nerve growth factor? Implications for cholinergic therapies in Alzheimer’s disease , 2001, Biological Psychiatry.

[181]  Agneta Nordberg,et al.  Nicotinic receptor abnormalities of Alzheimer’s disease: therapeutic implications , 2001, Biological Psychiatry.

[182]  Carmen Martin-Ruiz,et al.  Nicotinic receptor abnormalities in Alzheimer’s disease , 2001, Biological Psychiatry.

[183]  F. Dajas,et al.  Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra 1 1 Published on the World Wide Web on 1 December 2000. , 2001, Brain Research.

[184]  J. Cano,et al.  Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+‐induced neurotoxicity along with brain‐derived neurotrophic factor induction , 2001, Journal of neurochemistry.

[185]  Hiroshi Yamamoto,et al.  Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans , 2001, Clinical pharmacology and therapeutics.

[186]  G. Gilardi,et al.  Rational Design of P450 Enzymes for Biotechnology , 2001 .

[187]  F. Dajas,et al.  Involvement of nicotinic acetylcholine receptors in the protection of dopamine terminals in experimental parkinsonism. , 2001, Functional neurology.

[188]  S. Wonnacott,et al.  Neuronal nicotinic receptors , 2001 .

[189]  N. Inestrosa,et al.  The role of oxidative stress in the toxicity induced by amyloid β-peptide in Alzheimer’s disease , 2000, Progress in Neurobiology.

[190]  R. Robins,et al.  A short and efficient synthesis of unnatural (R)-nicotine , 2000 .

[191]  S. Hecht,et al.  2'-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[192]  R. Hurt,et al.  Modulation of nitric-oxide synthase by nicotine. , 2000, The Journal of pharmacology and experimental therapeutics.

[193]  A. Ballabio,et al.  The nicotinic receptor β2 subunit is mutant in nocturnal frontal lobe epilepsy , 2000, Nature Genetics.

[194]  R A Yokel,et al.  The toxicology of aluminum in the brain: a review. , 2000, Neurotoxicology.

[195]  Hoau Yan Wang,et al.  Amyloid Peptide Aβ1‐42 Binds Selectively and with Picomolar Affinity to α7 Nicotinic Acetylcholine Receptors , 2000 .

[196]  G. Kobal,et al.  Specific sensory detection, discrimination, and hedonic estimation of nicotine enantiomers in smokers and nonsmokers: are there limitations in replacing the sensory components of nicotine? , 2000, Journal of clinical psychopharmacology.

[197]  K. Fuxe,et al.  Central nicotinic receptors, neurotrophic factors and neuroprotection , 2000, Behavioural Brain Research.

[198]  A. Nordberg,et al.  Development of ligands for in vivo imaging of cerebral nicotinic receptors , 2000, Behavioural Brain Research.

[199]  T. Svensson,et al.  Role of α7 nicotinic receptors in nicotine dependence and implications for psychiatric illness , 2000, Behavioural Brain Research.

[200]  M. Smith,et al.  Oxidative stress in Alzheimer's disease. , 2000, Biochimica et biophysica acta.

[201]  A. Bush,et al.  Oxidative processes in Alzheimer's disease: the role of Aβ-metal interactions , 2000, Experimental Gerontology.

[202]  R. Tyndale,et al.  Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. , 2000, Biochemical pharmacology.

[203]  Agneta Nordberg,et al.  Neuronal nicotinic receptors in the human brain , 2000, Progress in Neurobiology.

[204]  M. Picciotto,et al.  Nicotinic Receptors in the Brain: Links between Molecular Biology and Behavior , 2000, Neuropsychopharmacology.

[205]  S. Hecht,et al.  Enantiomeric composition of N'-nitrosonornicotine and N'-nitrosoanatabine in tobacco. , 2000, Carcinogenesis.

[206]  E D Levin,et al.  Development of nicotinic drug therapy for cognitive disorders. , 2000, European journal of pharmacology.

[207]  R. Drucker-Colín,et al.  Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. , 2000, Archives of medical research.

[208]  P. Batel.  Addiction and schizophrenia , 2000, European Psychiatry.

[209]  P. A. Peterson,et al.  β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity , 2000, The Journal of Biological Chemistry.

[210]  A. Nordberg,et al.  Increased Levels of Tau Protein in SH‐SY5Y Cells After Treatment with Cholinesterase Inhibitors and Nicotinic Agonists , 2000, Journal of neurochemistry.

[211]  M. Williams,et al.  Neuronal nicotinic acetylcholine receptors as novel drug targets. , 2000, The Journal of pharmacology and experimental therapeutics.

[212]  Hiroshi Yamamoto,et al.  Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans , 2000, Clinical pharmacology and therapeutics.

[213]  David R. Lide,et al.  CRC handbook of chemistry and physics on CD-ROM , 2000 .

[214]  C. Evans,et al.  Free Radicals and Inflammation , 2000, Progress in Inflammation Research.

[215]  B. Dworakowska,et al.  Ion channels-related diseases. , 2000, Acta biochimica Polonica.

[216]  R. Buchet,et al.  Alzheimer's disease: its origin at the membrane, evidence and questions. , 2000, Acta Biochimica Polonica.

[217]  C. Masters,et al.  Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. , 1999, The Journal of biological chemistry.

[218]  A. C. Collins,et al.  Desensitization of nicotinic agonist-induced [3H]gamma-aminobutyric acid release from mouse brain synaptosomes is produced by subactivating concentrations of agonists. , 1999, The Journal of pharmacology and experimental therapeutics.

[219]  M. Damaj,et al.  Pharmacological Characterization of Nicotine-Induced Seizures in Mice 1 , 1999 .

[220]  E. Levin,et al.  AR-R 17779, an α7 nicotinic agonist, improves learning and memory in rats , 1999 .

[221]  A. Nordberg,et al.  Autoradiographic comparison of [3H](−)nicotine, [3H]cytisine and [3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease , 1999, Neuroscience.

[222]  S. Arneric,et al.  Structure-activity studies on a novel series of cholinergic channel activators based on a heteroaryl ether framework. , 1999, Bioorganic & medicinal chemistry letters.

[223]  M. Decker,et al.  Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics. , 1999, Biochemical pharmacology.

[224]  A. Nordberg,et al.  Synthesis and Characterization of Binding of 5‐[76Br] Bromo‐3‐[[2(S)‐Azetidinyl]methoxy]pyridine, a Novel Nicotinic Acetylcholine Receptor Ligand, in Rat Brain , 1999, Journal of neurochemistry.

[225]  H. McCauley,et al.  Optimization study for the reversed-phase ion-pair liquid chromatographic determination of nicotine in commercial tobacco products. , 1999, Journal of chromatography. A.

[226]  H. McCauley,et al.  Reversed phase ion-pair liquid chromatographic determination of nicotine in commercial tobacco products. 1. Moist snuff. , 1999, Journal of agricultural and food chemistry.

[227]  J. Schneider,et al.  Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. , 1999, The Journal of pharmacology and experimental therapeutics.

[228]  A. Nordberg,et al.  In vivo positron emission tomography studies on the novel nicotinic receptor agonist [11C]MPA compared with [11C]ABT-418 and (S)(-)[11C]nicotine in rhesus monkeys. , 1999, Nuclear medicine and biology.

[229]  N. Cosford,et al.  A Novel Method for the Racemization of 5-Bromonicotine. , 1999, The Journal of organic chemistry.

[230]  J P Changeux,et al.  International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. , 1999, Pharmacological reviews.

[231]  M. Sarter,et al.  Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats , 1999, Psychopharmacology.

[232]  G. Kobal,et al.  Dose-dependent stereoselective activation of the trigeminal sensory system by nicotine in man , 1999, Psychopharmacology.

[233]  J. Corwin,et al.  Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer’s disease , 1999, Psychopharmacology.

[234]  D. Armstrong,et al.  Enantiomeric composition of nornicotine, anatabine, and anabasine in tobacco , 1999 .

[235]  J. J. Langone,et al.  Chapter 8 – Use of immunoassay techniques for the determination of nicotine and its metabolites , 1999 .

[236]  J. W. Gorrod,et al.  Analytical determination of nicotine and related compounds and their metabolities , 1999 .

[237]  J. Gorrod,et al.  Chapter 3 – Biotransformation of nicotine in mammalian systems , 1999 .

[238]  G. Johnson,et al.  Tau protein in normal and Alzheimer's disease brain. , 1999, Journal of Alzheimer's disease : JAD.

[239]  H. Schröder,et al.  Nicotinic acetylcholine receptors in Alzheimer's disease. , 1999, Journal of Alzheimer's disease : JAD.

[240]  J. M. Garrigues,et al.  Fourier-transform infrared determination of nicotine in tobacco samples by transmittance measurements after leaching with CHCl3 , 1998 .

[241]  D J Healy,et al.  Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. , 1998, The American journal of psychiatry.

[242]  A. C. Collins,et al.  Pharmacological characterization of nicotinic receptor-stimulated GABA release from mouse brain synaptosomes. , 1998, The Journal of pharmacology and experimental therapeutics.

[243]  P. Cañizares,et al.  Recovery of Nicotine from Aqueous Extracts of Tobacco Wastes by an H+-Form Strong-Acid Ion Exchanger , 1998 .

[244]  D. Donnelly-roberts,et al.  Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice. , 1998, Bioorganic & medicinal chemistry letters.

[245]  D. Armstrong,et al.  Nicotine enantiomers and oxidative stress. , 1998, Toxicology.

[246]  E. London,et al.  2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. , 1998, Journal of medicinal chemistry.

[247]  T. Rao,et al.  Conformationally restricted analogues of nicotine and anabasine. , 1998, Bioorganic & medicinal chemistry letters.

[248]  R. Tyndale,et al.  Nicotine metabolism defect reduces smoking , 1998, Nature.

[249]  H. Hill,et al.  Analytical determination of nicotine in tobacco by supercritical fluid chromatography–ion mobility detection , 1998 .

[250]  Gary Walsh,et al.  Biopharmaceuticals: Biochemistry and Biotechnology , 1998 .

[251]  S. Hecht,et al.  Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. , 1998, Chemical research in toxicology.

[252]  S. Shimohama,et al.  Stimulation of α4β2 nicotinic acetylcholine receptors inhibits β-amyloid toxicity , 1998, Brain Research.

[253]  C. C. Johnson,et al.  The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living , 1998, Neurology.

[254]  J. Changeux,et al.  Allosteric nicotinic receptors, human pathologies , 1998, Journal of Physiology-Paris.

[255]  L. Edvinsson,et al.  Mechanism of nicotine-induced relaxation in the porcine basilar artery. , 1998, The Journal of pharmacology and experimental therapeutics.

[256]  D. Donnelly-roberts,et al.  Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. , 1998, Science.

[257]  D. Armstrong,et al.  Enantiomeric Composition of Nicotine in Smokeless Tobacco, Medicinal Products, and Commercial Reagents , 1998 .

[258]  W. Zielinski,et al.  Separation of nicotine and nornicotine enantiomers via normal phase HPLC on derivatized cellulose chiral stationary phases , 1998 .

[259]  L. Thal,et al.  Correlation of nicotinic binding with neurochemical markers in Alzheimer's disease , 1998, Journal of Neural Transmission.

[260]  W. J. Jackson,et al.  Central nicotinic receptor agonists ABT-418, ABT-089, and (–)-nicotine reduce distractibility in adult monkeys , 1998, Psychopharmacology.

[261]  J K Lynch,et al.  Neuronal nicotinic acetylcholine receptors as targets for drug discovery. , 1997, Journal of medicinal chemistry.

[262]  W. J. Jackson,et al.  ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. , 1997, The Journal of pharmacology and experimental therapeutics.

[263]  D. Donnelly-roberts,et al.  ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. , 1997, The Journal of pharmacology and experimental therapeutics.

[264]  R. Tyndale,et al.  A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. , 1997, The Journal of pharmacology and experimental therapeutics.

[265]  O. Wiklund,et al.  The nicotine inhaler in smoking cessation. , 1997, Archives of internal medicine.

[266]  S. Shimohama,et al.  Nicotinic receptor stimulation protects neurons against β‐amyloid toxicity , 1997 .

[267]  N. Benowitz,et al.  Cotinine effects on nicotine metabolism , 1997, Clinical pharmacology and therapeutics.

[268]  S. Dursun,et al.  Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette's syndrome: an open study , 1997, Psychological Medicine.

[269]  E X Albuquerque,et al.  Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. , 1997, The Journal of pharmacology and experimental therapeutics.

[270]  J. Glowinski,et al.  Nicotine-induced inhibition of neuronal phospholipase A2. , 1997, The Journal of pharmacology and experimental therapeutics.

[271]  A. D. Rodrigues,et al.  Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. , 1997, Journal of medicinal chemistry.

[272]  P. Dewick,et al.  Medicinal Natural Products: A Biosynthetic Approach , 1997 .

[273]  P. Sanberg,et al.  Nicotine for the treatment of Tourette's syndrome. , 1997, Pharmacology & therapeutics.

[274]  N. Benowitz,et al.  Individual differences in nicotine kinetics and metabolism in humans. , 1997, NIDA research monograph.

[275]  Y. Funae,et al.  Role of human cytochrome P4502A6 in C-oxidation of nicotine. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[276]  E. Levin,et al.  Nicotine–Haloperidol Interactions and Cognitive Performance in Schizophrenics , 1996, Neuropsychopharmacology.

[277]  R. Friedland,et al.  Nicotine inhibits amyloid formation by the beta-peptide. , 1996, Biochemistry.

[278]  M. Taskinen,et al.  Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance. , 1996, Circulation.

[279]  R. Olmstead,et al.  Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. , 1996, Addiction.

[280]  P. Adams,et al.  (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. , 1996, Journal of medicinal chemistry.

[281]  P. Sanberg,et al.  Transdermal nicotine for Tourette's syndrome , 1996 .

[282]  K. Fagerström,et al.  Clinical Pharmacokinetics of Nasal Nicotine Delivery , 1996, Clinical pharmacokinetics.

[283]  T. Jefferies,et al.  Optimization of Nicotine Extraction from Tobacco Using Supercritical Fluid Technology with Dynamic Extraction Modeling , 1996 .

[284]  Y. Funae,et al.  Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[285]  P. Sanberg,et al.  Free radical damage and oxidative stress in Huntington's disease. , 1996, The Journal of the Florida Medical Association.

[286]  D. Donnelly-roberts,et al.  Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. , 1996, Journal of medicinal chemistry.

[287]  F. Menzaghi,et al.  Epibatidine: a nicotinic acetylcholine receptor agonist releases monoaminergic neurotransmitters: in vitro and in vivo evidence in rats. , 1996, The Journal of pharmacology and experimental therapeutics.

[288]  S. Shimohama,et al.  Nicotine‐induced Protection Against Glutamate Cytotoxicity , 1996 .

[289]  U. Schneider,et al.  [Nicotine and Tourette's syndrome]. , 1996, Psychiatrische Praxis.

[290]  M. Jarvik,et al.  Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. , 1995, Addiction.

[291]  J. Wooten.  13C CPMAS NMR of bright and burley tobaccos , 1995 .

[292]  N. Funayama,et al.  Inhibitory effects of d-nicotine on the responses evoked by 1-isomer in trachea and bronchus isolated from guinea-pig and rabbit. , 1995, General pharmacology.

[293]  G. Wetscher,et al.  Free radical production in nicotine treated pancreatic tissue. , 1995, Free radical biology & medicine.

[294]  M. Billingsley,et al.  Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase. , 1995, Molecular pharmacology.

[295]  L. Dwoskin,et al.  Minor alkaloids of tobacco release [3H]dopamine from superfused rat striatal slices. , 1995, European journal of pharmacology.

[296]  T. Svensson,et al.  Nicotine dependence, midbrain dopamine systems and psychiatric disorders. , 1995, Pharmacology & toxicology.

[297]  O. Pelkonen,et al.  Individual Expression of Carcinogen-Metabolizing Enzymes: Cytochrome P4502A , 1995, Journal of occupational and environmental medicine.

[298]  A. Lawrence,et al.  Alzheimer disease, attention, and the cholinergic system. , 1995, Alzheimer disease and associated disorders.

[299]  S. Dursun,et al.  Longlasting improvement of Tourette's syndrome with transdermal nicotine , 1994, The Lancet.

[300]  W. Murphy,et al.  Distribution Coefficients of Nicotine between Hexane and Water , 1994 .

[301]  P. Whiting,et al.  Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. , 1994, Molecular pharmacology.

[302]  A. Nordberg.  Human nicotinic receptors—Their role in aging and dementia , 1994, Neurochemistry International.

[303]  T. Yaksh,et al.  Ligand specificity of nicotinic acetylcholine receptors in rat spinal cord: studies with nicotine and cytisine. , 1994, The Journal of pharmacology and experimental therapeutics.

[304]  T. Yaksh,et al.  Cardiovascular and behavioral responses to nicotinic agents administered intrathecally. , 1994, The Journal of pharmacology and experimental therapeutics.

[305]  A. Nordberg,et al.  Effects of chronic treatment with (+)- and (−)-nicotine on nicotinic acetylcholine receptors and N-methyl-d-aspartate receptors in rat brain , 1994, Brain Research.

[306]  M. S. Clarke,et al.  Nicotine stimulation of nerve growth factor receptor expression. , 1994, Life sciences.

[307]  W. Murphy,et al.  Countercurrent extraction of nicotine from tobacco juice , 1993 .

[308]  A. Nordberg.  Clinical studies in Alzheimer patients with positron emission tomography , 1993, Behavioural Brain Research.

[309]  N. Benowitz,et al.  Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1'-oxide. , 1993, Chemical research in toxicology.

[310]  N. Birbaumer,et al.  Comparison of a mechanized version of the 'König' reaction and a fluorescence polarization immunoassay for the determination of nicotine metabolites in urine. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[311]  A. Silver,et al.  Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome , 1993, The Lancet.

[312]  W. S. Caldwell,et al.  Intragastric Nitrosation of Nicotine Is Not a Significant Contributor to Nitrosamine Exposure , 1993, Annals of the New York Academy of Sciences.

[313]  N. Benowitz,et al.  Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers , 1993, Clinical pharmacology and therapeutics.

[314]  K. Rustemeier,et al.  HPLC separation of the enantiomers of nicotine and nicotine-like compounds , 1993 .

[315]  Jeffrey P. Jones,et al.  The binding and regioselectivity of reaction of (R)- and (S)-nicotine with cytochrome P-450cam: parallel experimental and theoretical studies , 1993 .

[316]  Langone Jj,et al.  Radioimmunoassay for nicotine and cotinine. , 1993 .

[317]  W. Oldendorf,et al.  Blood-brain barrier penetration abolished by N-methyl quaternization of nicotine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[318]  B. Långström,et al.  (S)- and (R)-[11C]nicotine and the metabolite (R/S)-[11C]cotinine. Preparation, metabolite studies and in vivo distribution in the human brain using PET. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[319]  H. Yamazaki,et al.  Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. , 1992, Carcinogenesis.

[320]  N. Benowitz,et al.  Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxide. , 1992, Chemical research in toxicology.

[321]  A. Terry,et al.  Selected biological activities of novel selenonium choline analogs. , 1992, General pharmacology.

[322]  H. Burton,et al.  Distribution of tobacco constituents in tobacco leaf tissue. 1. Tobacco-specific nitrosamines, nitrate, nitrite, and alkaloids , 1992 .

[323]  P. Sanberg,et al.  The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder , 1992, Biological Psychiatry.

[324]  L. Pannell,et al.  Epibatidine: a novel (chloropyridyl)azabicycloheptane with potent analgesic activity from an ecuadoran poison frog , 1992 .

[325]  Rickards Eh.  Nicotine gum in Tourette's disorder. , 1992 .

[326]  G. Byrd,et al.  Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-3'-hydroxycotinine in smokers. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[327]  P. Crooks,et al.  Characterization of the glucuronide conjugate of cotinine: a previously unidentified major metabolite of nicotine in smokers' urine. , 1992, Chemical research in toxicology.

[328]  S. Bronheim,et al.  Nicotine gum in Tourette's disorder. , 1992, The American journal of psychiatry.

[329]  K. Norris,et al.  Investigation into the applicability of diffuse reflectance and transmitance technology to tobacco analysis , 1992 .

[330]  Mera Sl.  Aluminium, amyloid, and Alzheimer's disease , 1991 .

[331]  N. Benowitz,et al.  Nicotine metabolism in humans , 1991, Clinical pharmacology and therapeutics.

[332]  W. S. Caldwell,et al.  The nitrosation of nicotine: a kinetic study. , 1991, Chemical research in toxicology.

[333]  J. Hughes.  Nicotine gum in general practice. , 1990, JAMA.

[334]  R. Obach,et al.  Radioimmunoassay of nicotine-delta 1'(5')-iminium ion, an intermediate formed during the metabolism of nicotine to cotinine. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[335]  S Wonnacott,et al.  The paradox of nicotinic acetylcholine receptor upregulation by nicotine. , 1990, Trends in pharmacological sciences.

[336]  R. Hoy,et al.  Fourier Transform Near-Infrared Spectrometry: Using Interferograms to Determine Chemical Composition , 1989 .

[337]  A. Nordberg,et al.  Uptake and regional distribution of (+)-(R)- and (−)-(S)-N-[methyl-11C]-nicotine in the brains of Rhesus monkey an attempt to study nicotinic receptors in vivo , 1989, Journal of neural transmission. Parkinson's disease and dementia section.

[338]  C. Godin,et al.  Enantioselective Metabolism During Continuous Administration of S‐(−)‐ and R‐(+)‐Nicotine Isomers to Guinea‐Pigs , 1988, The Journal of pharmacy and pharmacology.

[339]  P. Crooks,et al.  Effect of continuous administration of nicotine on urinary histamine and N tau-methylhistamine levels in the guinea pig. , 1988, Toxicology letters.

[340]  P. Crooks,et al.  Biotransformation of Primary Nicotine Metabolites: † Metabolism of R‐(+)‐[3H‐N′‐CH3; 14C‐N‐CH3] N‐Methylnicotinium Acetate—The Use of Double Isotope Studies to Determine the In‐vivo Stability of the N‐Methyl Groups of N‐Methylnicotinium Ion , 1988, The Journal of pharmacy and pharmacology.

[341]  P. Crooks,et al.  Inhibition of histamine N‐methyltransferase activity in guinea‐pig pulmonary alveolar macrophages by nicotine , 1988, The Journal of pharmacy and pharmacology.

[342]  N. Benowitz,et al.  Recent studies of nicotine metabolism in humans , 1988, Pharmacology Biochemistry and Behavior.

[343]  R. Hook,et al.  The comparative binding characteristics of nicotinic ligands and their pharmacology , 1988, Pharmacology Biochemistry and Behavior.

[344]  L. Peterson,et al.  Regio- and stereochemical studies on the alpha-carbon oxidation of (S)-nicotine by cytochrome P-450 model systems. , 1988, Journal of medicinal chemistry.

[345]  N. Benowitz,et al.  Effects of the stereoisomers of nicotine and nornicotine on schedule-controlled responding and physiological parameters of dogs. , 1988, The Journal of pharmacology and experimental therapeutics.

[346]  P. Crooks,et al.  N‐Methylation of nicotine enantiomers by human liver cytosol , 1988, The Journal of pharmacy and pharmacology.

[347]  A. Davies,et al.  The application of fourier-transformed near-infrared spectra to quantitative analysis by comparison of similarity indices (CARNAC) , 1988 .

[348]  O. Chortyk,et al.  Chemical composition of nonsmoking tobacco products , 1988 .

[349]  C. Altar,et al.  Receptor localization : ligand autoradiography , 1988 .

[350]  E. O. O. Smoking.  "The Health Consequences of Smoking: Nicotine Addiction: A Report of the Surgeon General" (Title Page through Table of Contents) , 1988 .

[351]  P. Crooks,et al.  Species variation and stereoselectivity in the metabolism of nicotine enantiomers. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.

[352]  U. Ribary,et al.  Prenatal adverse effects of nicotine on the developing brain. , 1988, Progress in brain research.

[353]  N. Benowitz,et al.  Prolonged absorption with development of tolerance to toxic effects after cutaneous exposure to nicotine , 1987, Clinical pharmacology and therapeutics.

[354]  L. Peterson,et al.  Stereochemical studies on the cytochrome P-450 catalyzed oxidation of (S)-nicotine to the (S)-nicotine delta 1'(5')-iminium species. , 1987, Journal of medicinal chemistry.

[355]  N. Monji,et al.  Nicotine enzyme immunoassay. , 1986, Research communications in chemical pathology and pharmacology.

[356]  R. Hook,et al.  Binding characteristics of (−)- and (+)-nicotine to the rat brain P2 fraction , 1985, Pharmacology Biochemistry and Behavior.

[357]  A. Scheman,et al.  Suicide plan by nicotine poisoning: a review of nicotine toxicity. , 1985, Veterinary and human toxicology.

[358]  R. Hook,et al.  Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation. , 1985, Journal of medicinal chemistry.

[359]  P. Crooks,et al.  Biotransformation of primary nicotine metabolites. I. In vivo metabolism of R-(+)-[14C-NCH3]N-methylnicotinium ion in the guinea pig. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[360]  B. Halliwell,et al.  Free radicals in biology and medicine , 1985 .

[361]  P. Crooks,et al.  Stereospecific in vivo N-methylation of nicotine in the guinea pig. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[362]  E. LaVoie,et al.  Nicotine: a precursor for carcinogens. , 1985, Cancer letters.

[363]  C. Feyerabend,et al.  Nicotine pharmacokinetics and its application to intake from smoking. , 1985, British journal of clinical pharmacology.

[364]  P. Crooks,et al.  High-performance liquid chromatography with electrochemical detection for the determination of nicotine and N-methylnicotinium ion. , 1985, Journal of chromatography.

[365]  P. Crooks,et al.  Evidence of stereospecificity in the in vivo methylation of [14C](+/-)-nicotine in the guinea pig. , 1984, Drug metabolism and disposition: the biological fate of chemicals.

[366]  W. M. Atkinson,et al.  Determination of nicotine in tobacco by circular dichroism spectropolarimetry , 1984 .

[367]  T. Yanagita,et al.  [Pharmacodynamic effects of d-nicotine--Comparison with l-nicotine]. , 1984, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[368]  J. Sloan,et al.  Nature of nicotine binding to rat brain P2 fraction , 1984, Pharmacology Biochemistry and Behavior.

[369]  W. F. McClure,et al.  Fourier Analysis Enhances NIR Diffuse Reflectance Spectroscopy , 1984 .

[370]  瞭 島田,et al.  d-Nicotineの薬理作用 ―l-Nicotineとの比較― , 1984 .

[371]  N. Benowitz,et al.  Cotinine disposition and effects , 1983, Clinical pharmacology and therapeutics.

[372]  R. Herning,et al.  Smokers of low-yield cigarettes do not consume less nicotine. , 1983, The New England journal of medicine.

[373]  Henningfield Je,et al.  Human pharmacology of nicotine. , 1983 .

[374]  B. Osborne,et al.  Near infrared analysis—today or tomorrow? , 1983 .

[375]  J. Sloan,et al.  Multiple nicotine binding sites in rat brain P2 fraction. , 1983, Psychopharmacology bulletin.

[376]  B. Martin,et al.  A Convenient Method for the Preparation of Racemic Nicotine , 1982 .

[377]  M. Fujiwara,et al.  The effects of d-nicotine and l-isomer on nicotinic receptors. , 1982, The Journal of pharmacology and experimental therapeutics.

[378]  R T Jones,et al.  Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. , 1982, The Journal of pharmacology and experimental therapeutics.

[379]  R. Spector,et al.  Active Transport of Nicotine by the Isolated Choroid Plexus In Vitro , 1982, Journal of neurochemistry.

[380]  Langone Jj,et al.  Radioimmunoassay of nicotine, cotinine, and gamma-(3-pyridyl)-gamma-oxo-N-methylbutyramide. , 1982 .

[381]  H. Nau,et al.  Nicotine and Cotinine – two pharmacologically active substances as parameters for the strain on fetuses and babies of mothers who smoke , 1982 .

[382]  M. Jarvis,et al.  Nicotine intake by snuff users. , 1981, British medical journal.

[383]  Curtis D. Klaassen,et al.  Casarett and Doull's Toxicology. The Basic Science of Poisons , 1981 .

[384]  J. Saunders,et al.  Quantitation of major tobacco alkaloids by high-performance liquid chromatography , 1981 .

[385]  N. Benowitz,et al.  Disposition kinetics and effects of intravenous nicotine , 1980, Clinical pharmacology and therapeutics.

[386]  M. Raw,et al.  Clinical use of nicotine chewing-gum. , 1980, British medical journal.

[387]  A. Tometsko,et al.  Separation of d-(+)-Nicotine from a Racemic Mixture by Stereospecific Degradation of the l-(−) Isomer with Pseudomonas putida , 1980, Applied and environmental microbiology.

[388]  D. Hoffmann,et al.  Chemical Studies on Tobacco Smoke LXVII. Quantitative Determination of Alkaloids in Tobacco by Liquid Chromatography , 1980 .

[389]  H. Vunakis.  [10] Radioimmunoassays: An overview , 1980 .

[390]  S. Hecht,et al.  Tobacco-Specific Nitrosamines: Occurrence, Formation, Carcinogenicity, and Metabolism , 2002 .

[391]  M. Aceto,et al.  Optically pure (+)-nicotine from (+/-)-nicotine and biological comparisons with (-)-nicotine. , 1979, Journal of medicinal chemistry.

[392]  B. Rabin.  Biological Oxidation of Nitrogen , 1978, British Journal of Cancer.

[393]  D. Hoffmann,et al.  Nitrogen-containing compounds in tobacco and tobacco smoke. , 1977 .

[394]  C. Dollery,et al.  Metabolism of nicotine by the isolated perfused dog lung. , 1975, Xenobiotica; the fate of foreign compounds in biological systems.

[395]  S. Gehlbach,et al.  NICOTINE ABSORPTION BY WORKERS HARVESTING GREEN TOBACCO , 1975, The Lancet.

[396]  S. Mirvish.  Formation of N-nitroso compounds: chemistry, kinetics, and in vivo occurrence. , 1975, Toxicology and applied pharmacology.

[397]  W H Oldendorf,et al.  Lipid Solubility and Drug Penetration of the Blood Brain Barrier , 1974, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[398]  J. J. Langone,et al.  Nicotine and cotinine in the amniotic fluid of smokers in the second trimester of pregnancy. , 1974, American journal of obstetrics and gynecology.

[399]  J. J. Langone,et al.  Nicotine and its metabolites. Radioimmunoassays for nicotine and cotinine. , 1973, Biochemistry.

[400]  P. Murphy.  Enzymatic oxidation of nicotine to nicotine 1'(5') iminium ion. A newly discovered intermediate in the metabolism of nicotine. , 1973, The Journal of biological chemistry.

[401]  P. Jenner,et al.  The absorption of nicotine-1'-N-oxide and its reduction in the gastro-intestinal tract in man. , 1973, Xenobiotica; the fate of foreign compounds in biological systems.

[402]  T. Stålhandske.  Effects of increased liver metabolism of nicotine on its uptake, elimination and toxicity in mice. , 1970, Acta physiologica Scandinavica.

[403]  A. K. ARMITAGE,et al.  Absorption of Nicotine in Cigarette and Cigar Smoke through the Oral Mucosa , 1970, Nature.

[404]  R. Stedman.  The chemical composition of tobacco and tobacco smoke. , 1968, Chemical reviews.

[405]  L. Appelgren,et al.  DISTRIBUTION OF NICOTINE IN THE CENTRAL NERVOUS SYSTEM , 1967 .

[406]  J. T. Hamilton,et al.  The stereospecificity of nicotine. , 1965, British journal of pharmacology and chemotherapy.

[407]  A. W. Sangster,et al.  Ultraviolet Spectra of Alkaloids , 1965 .

[408]  L. Turnbull,et al.  N-Methylation of nicotine ad cotinine in vivo. , 1963, The Journal of biological chemistry.

[409]  J. Travell.  ABSORPTION OF NICOTINE FROM VARIOUS SITES , 1960, Annals of the New York Academy of Sciences.

[410]  R. Johnstone,et al.  The Chemical Constituents Of Tobacco And Tobacco Smoke , 1959 .

[411]  R. Cundiff,et al.  Determination of Nicotine, Nornicotine, and Total Alkaloids in Tobacco , 1955 .

[412]  F. Houston.  Separation and Determination of Nicotine and Nornicotine in Tobacco , 1952 .

[413]  J. Willaman.  Alkaloids of Tobacco. Identification and Determination , 1952 .

[414]  C. Badgett.  Solvents for Extracting Nicotine from Aqueous Solutions , 1950 .

[415]  W. Barthel,et al.  Determination of Nicotine and Nornicotine in Tobaccos , 1943 .

[416]  L. Norton.  Distribution of Nicotine between Water and Petroleum Oils. , 1940 .

[417]  L. Craig.  A New Synthesis of Nornicotine and Nicotine , 1933 .

[418]  J. Faulkner,et al.  NICOTINE POISONING BY ABSORPTION THROUGH THE SKIN , 1933 .